Axonis Therapeutics is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders
Axonis Therapeutics is a leading biotechnology company dedicated to advancing innovative therapies for neurological disorders. With a focus on neuroregeneration, neuroprotection, and neuromodulation, Axonis Therapeutics is committed to developing first-in-class medicines that address unmet needs in the treatment of brain-related conditions.
Based in Boston, Massachusetts, with its primary address at 75 Kneeland St, 14th Floor, Boston, Massachusetts 02111, US, Axonis Therapeutics operates at the forefront of drug discovery, leveraging breakthrough discoveries to target KCC2, a critical mediator of inhibitory neurotransmission. The company's proprietary KCC2 discovery engine and lead development candidate, AXN-027, exemplify its dedication to pioneering advancements in the field.
Axonis Therapeutics is poised for continued growth and impact, driven by its commitment to innovation and strategic partnerships. The company's management is actively working to provide further details about its ongoing projects and future initiatives. We invite the manager of Axonis Therapeutics to create a customized and exclusive company showcase and product listing on our platform.
Axonis Therapeutics est une société de biotechnologie de premier plan dédiée à l'avancement de thérapies innovantes pour les troubles neurologiques. En mettant l'accent sur la neuro-régénération, la neuroprotection et la neuromodulation, Axonis Therapeutics s'engage à développer des médicaments de premier ordre qui répondent aux besoins non satisfaits dans le traitement des affections cérébrales.
Basée à Boston, Massachusetts, avec son adresse principale au 75 Kneeland St, 14th Floor, Boston, Massachusetts 02111, US, Axonis Therapeutics opère à l'avant-garde de la découverte de médicaments, tirant parti de découvertes révolutionnaires pour cibler KCC2, un médiateur essentiel de la neurotransmission inhibitrice. Le moteur de découverte KCC2 exclusif de la société et le principal candidat au développement, AXN-027, illustrent son dévouement à l'avancement pionnier dans le domaine.
Axonis Therapeutics est sur le point de connaître une croissance et un impact continus, grâce à son engagement envers l'innovation et les partenariats stratégiques. La direction de l'entreprise s'efforce activement de fournir de plus amples détails sur ses projets en cours et ses initiatives futures. Nous invitons le responsable d'Axonis Therapeutics à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme.
Compare Axonis Therapeutics with 3 companies in Biotechnology
| Comparison Field |
Axonis TherapeuticsMain Company |
Foundation for Negle...View Profile |
Alloy Therapeutics,...View Profile |
AMPLY DiscoveryView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2014 | 2017 | 2021 |
|
Company Size
|
— | 11-50 | 51-200 | 2-10 |
|
City
|
Boston, Massachusetts | Bangalore, Karnataka | Boston, Massachusetts | Belfast, Northern Ireland |
|
Country
|
United States | India | United States | United Kingdom |
|
Skills & Keywords
Comparing with main company
|
7 Total Skills
Biotechnology
Neurological Disorders
Neuroregeneration
Neuroprotection
Neuromodulation
Drug Discovery
KCC2 Target
|
7 Total
7 Unique
Unique Skills:
Diagnostics Research
Infectious Diseases
Malaria
Microbiology
Neglected Diseaes
Preclinical Research
+1
|
12 Total
12 Unique
Unique Skills:
ASO
Biologics Discovery
Biotech
Bispecific Antibodies
Chimeric Antigen Receptors
Company Creation
+6
|
13 Total
13 Unique
Unique Skills:
AI
Animal Health
Anti-infectives
Bioinformatics
Biologics
Cancer
+7
|
Other organizations in the same industry
This company is also known as